Unraveling Mechanisms that Control Platelet Production

Joseph E. Italiano, Jr., PhD

1 Division of Hematology, Brigham and Women’s Hospital, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts


Abstract

Platelets are formed by giant precursor cells called megakaryocytes that reside within the bone marrow. The generation of platelets, and their release into the bloodstream by megakaryocytes, requires a complex series of remodeling events powered by the cytoskeleton to result in the release of many platelets from a single megakaryocyte. Abnormalities in this process can result in thrombocytopenia (low platelet count) and can lead to increased risk of bleeding. This review describes the process of platelet production in detail and discusses new insights into novel platelet biology.

Keywords
- megakaryocyte
- platelet
- proplatelet
- thrombopoiesis
- cytoskeleton

Blood platelets, tiny cells shed by megakaryocytes, circulate throughout blood vessels and survey the integrity of the vascular system. Each day an adult produces about 100 billion platelets. Although our understanding of platelet production has grown considerably in recent years, the mechanisms by which platelets are produced from megakaryocytes largely remains to be defined. The development of megakaryocyte cultures that produce bona fide platelets has provided a means to study the intermediate structures called “proplatelets,” long, thin extensions of the megakaryocyte cytoplasm that function as assembly lines for platelet production. This article represents an integrated review on the mechanisms of platelet production. Because the cytoskeleton provides the force to power the production of platelets, this review first considers the cytoskeletal elements that provide the structure of the resting platelet cytoskeleton. The review then focuses on the mechanisms that lead to the elaboration of proplatelets and release of individual platelets. Also discussed are the new and emerging roles of platelets that extend beyond thrombosis and hemostasis.

Structure and Cytoskeleton of Circulating Platelets

Megakaryocyte development culminates with the release of mature discoid platelets with average dimensions of 3.0 × 5.0 μm. The plasma membrane of the resting platelet is replete with transmembrane receptors. As much as 20% of the surface area is occupied with receptors, which include ligands for thrombin, IgG (FcγRIIA), and the major surface glycoproteins GPαIIbβ3 and GPIb/IX/V. The cytoplasm of platelets contains two types of secretory granules: dense- and α-granules. The disc shape of the platelet is maintained by a very unique and specialized cytoskeleton, which functions as the molecular struts and girders of the cell. The main components of the platelet cytoskeleton are a marginal microtubule coiled repeatedly into a band, a spectrin-based membrane skeleton, and a three-dimensional network of cross-linked actin filaments.

The marginal band of resting platelets is located at the cell periphery and consists of multiple microtubules, coiled up 8 to 12 times. Microtubules are long, hollow polymers formed from tubulin dimers that provide the force for movement in many cellular functions, including mitotic chromosome segregation as well as organelle translocation. Platelets and megakaryocytes contain primarily the β-1 isoform of tubulin. β-1 Tubulin is the most highly divergent β tubulin isoform and is hematopoietic specific. Analysis of β-1 tubulin knockout mice points to a critical cellular function for β-1 tubulin in platelet biogenesis. These mice exhibit a bleeding phenotype, have reduced platelets, and contain defective microtubule coils. Consistent with these observations, a mutation in the human β-1 tubulin gene has been identified, and analysis has revealed large spherical platelets with a microtubule coil that is highly disorganized. Platelets also contain the motor proteins cytoplasmic dynein and kinesin, which can bind to...
microtubules and exert force. The generation of the microtubule coil is a critical event in the final stages of platelet production, and the mechanisms of its construction are discussed in more detail later in this review.

An elaborate network of spectrin and associated proteins laminates the underside and provides structural support for the plasma membrane of the resting platelet. The spectrin strands interact to form a hexagonal lattice and are densely decorated with attached membrane glycoprotein. The platelet spectrin network is structurally similar to the membrane skeleton of the erythrocyte, except its spectrin molecules interconnect to actin using the ends of long filaments instead of short oligomers of actin. Individual molecules of actin come together to form short oligomers that subsequently undergo assembly into long filaments. Actin is the most abundant of all proteins in platelets, making up about 20% of the total protein. The filamentous actin element of resting platelets is arranged into approximately 2,000 actin filaments that are interconnected, at various points, into a rigid network by the actin crosslinking protein filamin A (FLNa). FLNa subunits self-associate in solution into long homodimers. FLNb is expressed in platelets at one-tenth the level of FLNa (12,000 copies/platelet). Andrews and Fox were the first to discover that FLNa links GPIb/IX/V, which forms the von Willebrand factor receptor on the platelet membrane, to actin filaments in the cytoplasm. The second rod domain of FLNa (repeat 17) has a binding site for the cytoplasmic tail of GPIb-α component of GPIb/IX/V, and cell biologic experiments have shown that most platelet FLNa (≥ 90%) is in complex with GPIb-α. Because a large percentage of FLNa is attached to actin, it positions the von Willebrand factor receptor on the surface of the platelet over the underlying linear filaments in the platelet cytoskeleton. Platelets from patients with Bernard–Soulier syndrome (who lack the von Willebrand factor receptor) also lack this connection, and their platelets are unusually large and fragile. As Bernard–Soulier syndrome patients have a severe bleeding diathesis and thrombocytopenia, this suggests that GPIb/IX/V is important for normal platelet generation. This possibility is further suggested by the low platelet count and unusual morphology of platelets observed in mice lacking the GPIb-α receptor. Although the FLNa–von Willebrand factor receptor connection has been characterized at length in platelets, the role of this molecular linkage in platelet production is not fully understood.

Mechanisms of Platelet Production

Proplatelet Model of Platelet Production

Megakaryocytes are highly specialized cells that expand and become polyploid through a process called endomitosis. As megakaryocytes develop, their cytoplasm increases in size and becomes full of platelet-specific granules; at the same time the megakaryocyte develops a highly invaginated demarcation membrane system. Megakaryocyte maturation comes to completion with the release of platelets into the bloodstream. Past studies focusing on the mechanics of this process have been hindered by the rarity of megakaryocytes in the bone marrow (< 0.1% of the total cells) and the lack of in vitro systems that faithfully reconstitute platelet biogenesis. However, the discovery of thrombopoietin, the major cytokine that regulates the growth and development of megakaryocytes, and the emergence of cell culture systems that reconstitute bona fide platelet generation have resulted in substantial progress toward understanding the maturation of megakaryocytes.

The currently favored model of platelet production recognizes that differentiated megakaryocytes extend long cytoplasmic processes, designated proplatelets. Proplatelets function as the assembly lines of platelet production and comprise platelet-sized swellings in tandem arrays that are linked by thin cytoplasmic bridges (Fig. 1). Although extensive characterization of proplatelets remains incomplete, these processes have been recognized both in vitro and in vivo, and proplatelet-producing megakaryocytes generate platelets that are structurally and functionally similar to blood platelets. Proplatelets have been observed extending from megakaryocytes in the bone marrow through junctions in the lining of blood sinuses where they have been hypothesized to be released into the circulation and undergo additional fragmentation into platelets. Furthermore, mice

![Fig. 1](image-url) Generation of proplatelets by a mouse megakaryocyte. Time-lapse sequence of a megakaryocyte, showing the essential events that lead to elaboration of proplatelets in vitro. (A) Platelet production starts when the megakaryocyte cytoplasm starts to erode at one pole (arrow). (B) The majority of the megakaryocyte cytoplasm has been converted into multiple proplatelet processes that continue to lengthen and form swellings along their length. These processes are highly dynamic and undergo bending and branching. (C) Once the bulk of the cytoplasm has been converted into proplatelets, the entire process ends in a rapid retraction that separates the released proplatelets from the residual cell body. (Adapted from: Italiano J.E Jr., Lecine P, Shvidasani RA, Hartwig JH. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol 1999;147(6):1299–1312.)
lacking distinct hematopoietic transcription factors, such as nuclear factor erythroid-derived 2, have severe thrombocytopenia and fail to produce proplatelets in vitro, highlighting the parallel to platelet genesis in vivo. Before proplatelet-based models, platelets were thought to form in the cytoplasm of the megakaryocyte and undergo fragmentation along the boundaries of the demarcation membrane system. However, evidence now indicates the primary role of the demarcation membrane system is to serve as an extensive membrane reservoir that is required for proplatelet elaboration. The exact mechanism and the locations of platelet production are, however, still controversial. Production of platelets from megakaryocytes within capillary beds has been proposed as an alternative mechanism, but it is difficult to demonstrate in the mouse or other species. Proplatelet formation, originally identified within bone marrow sinusoids, may also take place partially in the bloodstream.

**Stages of Platelet Production**

The development of megakaryocyte cultures that faithfully reconstitute platelet formation has provided model systems to study megakaryocytes in the act of forming proplatelets. Live cell microscopy reveals both spatial and temporal changes leading to the generation of proplatelets. Remodeling of the megakaryocyte cytoplasm concentrates almost all the intracellular contents into proplatelet processes and their platelet-size particles, which, in the final stages, appear as beads linked by thin cytoplasmic bridges. The transformation unfolds over 3 to 10 hours and begins in a polarized fashion with the erosion of one side of the megakaryocyte cytoplasm. Thick pseudopodia-like processes initially form and then extend into thin tubes of uniform diameter of 2 to 4 μm. The thin tubes subsequently undergo a dynamic bending and branching process and develop periodic platelet-sized swellings that span their length. Ultimately, the megakaryocyte is converted into a residual naked nucleus surrounded by an elaborate network of proplatelets. Megakaryocyte matura
tion ends when a fast retraction that separates the proplatelet fragments from the cell body releases the processes into culture. The subsequent rupture of the cytoplasmic bridges between platelet-size segments is thought to release individual platelets into the circulation.

**Microtubules Power the Elongation of Proplatelets**

Some of the first insights into the cytoskeletal mechanisms that power platelet formation dates from the work of Tablin and Leven, who used microtubule inhibitors to establish that proplatelet extension is dependent on microtubules. The megakaryocyte cytoskeleton, which is composed of microtubules, actin, and spectrin, functions as the engine that powers the production of platelets. Proplatelet formation and elongation is dependent on microtubule function, because treatment of megakaryocytes with drugs that disassemble microtubules, such as vincristine or nocodazole, blocks proplatelet formation. Examination of the microtubule cytoskeletons of proplatelet-producing megakaryocytes provides insights into how microtubules contribute to platelet production. The microtubule cytoskeleton in megakaryocytes undergoes a striking remodeling during proplatelet production. In immature, round megakaryocytes without proplatelets, microtubules extend out from the cell center (centrosome) to the cortex. As thick pseudopodial processes form during the early stage of proplatelet production, cortical microtubules combine into thick bundles located under the plasma membrane of these structures. When pseudopodia start to extend (at an average rate of about 0.85 μm/min), microtubules form thick linear arrays that core the length of the proplatelets. The bundles of

<table>
<thead>
<tr>
<th>Cytoskeletal component</th>
<th>Major function(s) in platelet production</th>
</tr>
</thead>
<tbody>
<tr>
<td>Microtubules</td>
<td>Proplatelet elongation</td>
</tr>
<tr>
<td>Actin</td>
<td>Proplatelet bending and branching</td>
</tr>
<tr>
<td>Spectrin</td>
<td>Formation of the invaginated membrane system and stabilization of proplatelet architecture.</td>
</tr>
</tbody>
</table>
Unraveling Mechanisms that Control Platelet Production

Microtubules are thickest in the region of the proplatelet near the body of the megakaryocyte but then thin to bundles of 5 to 10 microtubules near the tips of proplatelets. The distal end of each proplatelet always has a platelet-size enlargement containing a microtubule bundle that makes a U-turn and loops just beneath the plasma membrane and reenters the shaft to form a tear-drop-shaped or tennis racket-shaped structure. Because microtubule coils similar to those observed in blood platelets are detected only at the tips of proplatelets and not within the platelet-size swellings found along the length of proplatelets, putative platelets are generated only at the ends of proplatelets.

By directly visualizing microtubule dynamics in living megakaryocytes using green fluorescent protein technology, we have obtained insights into how microtubules provide the force to power proplatelet elongation. End-binding protein three (EB3), a microtubule plus-end-binding protein associated only with growing microtubules, attached to green fluorescent protein (GFP) was retirovirally expressed in mouse megakaryocytes and used as a marker to track the dynamics of microtubule plus ends. Round, immature megakaryocytes without proplatelets use a centrosomal-coupled microtubule nucleation/assembly reaction, which appears as a prominent starburst pattern when visualized with EB3-GFP. Microtubules assemble only from the centrosomes and grow outward into the cell cortex, where they turn and run in parallel with the cell edges. However, just before proplatelet production commences, centrosomal assembly ceases and microtubules begin to condense into the cortex. Fluorescence time-lapse microscopy of proplatelet-producing megakaryocytes expressing EB3-GFP demonstrates that as proplatelets extend, microtubule polymerization takes place constantly throughout the entire length of the proplatelet, including the tip, swellings, and shaft. The rates of microtubule assembly (average, 10.2 μm/min) are about 10-fold faster than the rate at which proplatelets grow, suggesting assembly and proplatelet elongation are not tightly coupled. The EB3-GFP studies also demonstrated that microtubules assemble in both directions in proplatelets. This reveals that the microtubules within the bundles have a mixed polarity (Fig. 5).

Although microtubules are constantly assembling in proplatelets, polymerization by itself does not supply the force for proplatelet elongation. Proplatelets continue to extend at normal rates even when microtubule assembly is momentarily blocked by drugs that inhibit net microtubule polymerization, suggesting an alternative mechanism for proplatelet extension. In line with this idea, proplatelets have an internal microtubule sliding mechanism. The minus-end directed microtubule molecular motor protein cytoplasmic dynein...
localizes along the length of microtubules of the proplatelet. Cytoplasmic dynein appears to participate directly in microtubule sliding, because inhibition of cytoplasmic dynein, through dissociation of the dynactin complex, blocks proplatelet formation. Microtubule sliding can also be reactivated in permeabilized proplatelets. Addition of ATP, known to support the enzymatic activity of microtubule-based molecular motors, activates proplatelet elongation in the permeabilized proplatelets that contain both cytoplasmic dynein and its regulatory complex called dynactin. Thus, dynein-driven microtubule sliding appears to be a crucial event in powering proplatelet elongation.

Amplification of Proplatelet Ends via Bending and Branching
At the same time as the microtubule system is used to propel the extension of proplatelets, an actin-powered process is used to branch off the shaft of the proplatelet, in so doing increasing the number of proplatelet tips available to participate in platelet production (Fig. 6). This unique process starts when a region of the proplatelet shaft is bent into a U-shape. A new daughter process next juts out from the middle of this bend and extends. Some of the microtubules within the bent segment of the loop separate from the bundle to form a bulge. Sliding and polymerization of these microtubules creates a new daughter proplatelet process.17 This branching mechanism is driven by actin-based forces and is inhibited when megakaryocytes are treated with drugs such as the cytochalasins, a family of toxins that block actin monomers from polymerizing. Although the precise details on how the actin cytoskeleton powers this event are lacking, actin filament assemblies occur periodically along the length of the proplatelet shaft and are used as muscles to bend the rigid microtubules. At these locations, actin filaments polymerize; although much is known about the regulation of actin polymerization in platelets, there is very little information on how actin polymerization is regulated or stimulated at these locations along proplatelets. Strong connections between the microtubules and the actin filaments must be established to transmit the actin-powered bending forces to the microtubule bundle. One possibility is that actin filament–associated myosin motors may provide the force for bending. Myosins comprise a family of molecular motor proteins most known for their role in the contraction of muscle and a wide range of other motilities. Certain diseases suggest an important role for myosin II in platelet generation. Mutations of MYH9 (the gene that encodes myosin IIA) that modify myosin IIA at the site involved in myosin thick filament formation are implicated in MYH9-related disorders (e.g., May–Hegglin anomaly, Sebastian syndrome), a disorder where platelet numbers are reduced in numbers and are abnormally large.

Mechanisms of Organelle Transport and Capture during Platelet Production
Essential in the process of platelet generation is the distribution of granules and organelles into nascent platelets. In addition to functioning as the primary machinery to elongate proplatelets, the microtubules that line the length of proplatelets provide a secondary role—highways for the transport and delivery of membrane, organelles, and granules into proplatelets and assembling platelets at the ends of proplatelets. By monitoring the distribution and dynamics of organelles/granules in living cells, it was established that individual organelles are sent one by one from the megakaryocyte body into the proplatelets, where they move in both directions until they are captured at the ends of proplatelets.21
Thin-section electron microscopy and fluorescence microscopy studies indicate that organelles are in direct contact with microtubules, and actin inhibitors do not block the motion of organelles. Thus, motility appears to involve microtubule-based forces. Microtubules are polar structures with a clearly defined directionality, as indicated by a plus and minus end. The bidirectional movement of organelles is imparted by the bipolar organization of microtubules within the proplatelet. Beads coated with the molecular motor kinesin, which only moves in the plus-end direction, translocate in both directions over the microtubules within permeabilized proplatelets. Of the two major microtubule-based motors, only the plus-end-directed kinesin is located in a pattern similar to organelles and is most likely responsible for translocating these cargo along microtubules. Taken together, the data suggest that a twofold mechanism of organelle movement occurs during platelet production. First, organelles and granules move along microtubules, and, second, the microtubules themselves can slide in relation to other motile filaments to move organelles along proplatelets.

### Spectrin-Based Membrane Skeleton in Platelet Production

Although the role of microtubules and actin filaments in platelet production have been analyzed at length, the role of the membrane skeleton in this process has only recently emerged. Rapid-freeze high-resolution electron microscopy reveals that proplatelets contain a dense membrane skeleton similar in structure to that observed in the platelets in blood. The main fibrous component of this skeleton is spectrin. The nonerythroid spectrin subunits, β-II and α-II spectrin, are predominately expressed in megakaryocytes, proplatelets, and platelets. However, erythroid β-I and α-I spectrin isoforms are also present. Assembly of spectrin tetramers is required for generation of the invaginated demarcation membrane system and ultimately proplatelet production because expression of a spectrin tetramer-disrupting peptide in megakaryocytes inhibits the progression of both. In addition, introduction of this spectrin-disrupting construct into a detergent-permeabilized model system rapidly destabilizes proplatelet morphology, resulting in enormous swelling and blebbing. Spectrin tetramers also stabilize the barbell shapes of the penultimate stage in platelet generation from proplatelets. Taken together, these observations suggest a role for spectrin in distinct events of megakaryocyte development through its participation in the generation of demarcation membranes and in the maintenance of proplatelet structure.

### Release of Individual Platelets

In vivo, proplatelets extend into bone marrow vascular sinusoids, where they are released and enter the bloodstream. Previously, our understanding of platelet release was based on static images of scanning electron micrographs of the bone marrow sinusoids. More recently, Junt and colleagues have used intravital fluorescence microscopy to directly visualize proplatelet production in the opened cranial marrow cavity of living mice. Fluorescently labeled megakaryocytes could be seen to protrude proplatelets and release megakaryocyte

---

**Fig. 6** Bending and branching of proplatelets. The bifurcation of proplatelets is observed in these phase-contrast images taken 10 minutes apart showing the bending and branching of a proplatelet extension. The bends are converted into loops that become compressed and extend, resulting in a bifurcation of the original tube. White arrowheads indicate the branch points. (Adapted from: Italiano JE Jr., Lecine P, Shivdasani RA, Hartwig JH. Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. *J Cell Biol* 1999;147(6):1299–1312.)
fragments into the marrow sinusoids of living mice. Notably, these anucleate mekaryocyte fragments typically exceed platelet dimensions, suggesting that platelet morphogenesis continues in the circulation. In line with these observations, we identified a previously unrecognized intermediate stage in platelet formation and release, which we termed the preplatelet. Preplatelets, which appear as “giant discoid platelets,” 3 to 10 μm in diameter, retain the capacity to convert into barbell-shaped proplatelets and undergo fission into individual platelets. Inhibitors of microtubule assembly block the transition of preplatelets to barbells. Furthermore, taxol, which stabilizes microtubules and stimulates microtubule polymerization, promotes the conversion of preplatelets into platelets. Thus, the conversion of preplatelets to barbells is powered by microtubule-based forces. In support of this concept, laser scanning cytometry modeling suggests that platelet size is limited by microtubule coiling. Force constraints deriving from cortical microtubule band diameter and thickness play a major role in determining barbell conversion, and mathematical modeling suggests that platelet size is limited by microtubule bundling, elastic bending, and actin-myosin-spectrin cortical forces. In support of this concept, laser scanning cytometry has provided high-resolution images of both preplatelets and barbell-shapes in blood. It was demonstrated that individual human platelets have the innate capacity to duplicate and form new cell bodies that undergo fission into platelets. The morphologic similarities between platelets that form new cell bodies and preplatelets are striking. Whether or not newly released platelets exhibit a preplatelet phenotype, which may allow them to form barbell shapes and divide again, is not clear.

**Translating Thrombopoiesis Biology into Medicine**

It has been 17 years since the discovery of thrombopoietin, and drugs that are thrombopoietin mimetics are beginning to make an impact on the treatment of thrombocytopenia. Despite this progress, we need to address the next major advances in this field. In the United States alone more than 2 million platelet transfusions occur each year, all with platelets from volunteer donors. Because of their essential role in hemostasis, platelets are used for patients who have experienced traumatic injury or are undergoing chemotherapy. The supply of platelets has long been a problem for hospitals and blood banks. The short storage time (5 days) of platelet products, which must be kept at room temperature, is also a challenge. In addition, the risk of transfusion of transmitted diseases and shortages in supply provide additional problems associated with donor platelets. Clearly, the ability to continuously generate platelets ex vivo in a bioreactor would provide a more advanced way to generate a product to treat thrombocytopenia. Since thrombopoietin was identified as the major regulator of platelet production, it has been used to make enriched populations of megakaryocytes. In 1995 Choi and colleagues demonstrated that platelets generated in vitro from proplatelet-displaying human megakaryocytes were functional. Since then, both megakaryocytes and platelets have been differentiated from multiple sources, including embryonic stem cells and induced pluripotent stem cells. However, despite all these various sources of megakaryocytes and platelets, the yields of in vivo generated platelets have not come close to what is necessary for clinical application. In the bone marrow, specialized microenvironments, called niches, regulate megakaryocyte development and platelet production through a complex crosstalk between many cell types. The establishment of an in vitro model that faithfully recapitulates the fundamental interactions of the niche components in a controlled setting could advance the development of in vitro platelets for transfusion. For example, Lasky and colleagues have constructed a purpose-built three-dimensional hydrogel scaffold that functions as a bioreactor for platelet production. In this system, the authors used CD34 positively selected human cord blood cells in a three-dimensional hydrogel scaffold coated with thrombopoietin and/or fibronectin to increase platelet output. In this three-dimensional model, the manipulation of oxygenation and flow-induced shear stress appears to increase the yield of in vitro platelets derived from cord blood. Building on these models, Pallotta and colleagues have also recently developed a silk-based three-dimensional system that partially recapitulates the spatial reconstruction of the bone marrow environment and produces platelets in vitro. Overall, these advances suggest that it will be important to mimic physiology and use biologically inspired engineering to advance this technology to the clinic.

**Platelets: Not Just the Band-Aids of the Blood**

Although their primary function is to prevent bleeding, recent data suggest that platelets contribute to a diverse array of processes that go way beyond thrombosis and hemostasis. Platelets have been implicated in many different processes, including the development of the lymphatic system, liver regeneration, inflammation, and cancer. From the perspective of platelet production, it will be important to understand how platelet generation is altered or “reprogrammed” to affect these other functions. We have recently investigated how platelets regulate angiogenesis and innate immunity.

**Platelets and New Blood Vessel Growth**

A body of clinical and experimental data suggest that platelets influence tumor development by transporting and delivering angiogenesis regulatory proteins. The ability of platelets to interact with the endothelium is a key factor that allows them to regulate angiogenesis. Some of the first data suggesting that platelets can modulate angiogenesis were reported by Gimbrone et al., who demonstrated that perfusion of plasma depleted of blood platelets resulted in instability of the endothelial layer and hemorrhages. Other studies in animals demonstrated that absence of platelets or low
platelet count led to increased permeability of the vasculature, the likely result of excessive space between endothelial cells. It was later demonstrated that platelets modulate angiogenesis by showing that platelets could stimulate the formation of capillary-like and tubulike structures when added to human umbilical vein endothelial cells in culture. Although platelets have been presumed to contribute to tumor development by providing numerous stimulators and inhibitors of angiogenesis, the regulatory role of platelets in this process is not fully understood. Platelets contain numerous regulators of new blood vessel growth, which can be delivered to the endothelium when platelets activate. The proangiogenic regulatory proteins vascular endothelial growth factor, platelet-derived growth factor, epithelial growth factor, basic fibroblast growth factor, metalloproteinases, and sphingosine 1-phosphate have all been identified in platelets. The stimulators in platelets are counterbalanced by the platelet angiogenesis inhibitors, including platelet factor 4, thrombospondin-1, endostatin, tissue inhibitor of matrix metalloproteinases, and angiostatin. Most angiogenesis regulatory proteins identified in platelets have been localized to α-granules, the major storage granule of platelets. Each human platelet contains about 40 to 80 α-granules. By attaching to the endothelium of injured vessels and then releasing their contents, platelets deliver high concentrations of angiogenesis regulatory proteins in a precise manner.

The levels of these angiogenic regulatory proteins in platelets appear to play a role in tumor angiogenesis. It has been reported that when a microscopically sized human tumor is present in a mouse, circulating platelets take up and sequester specific angiogenesis regulatory proteins, such as platelet factor 4, vascular endothelial growth factor, and basic fibroblast growth factor. The angiogenic regulatory proteins are sequestered in the platelets at a significantly higher concentration than is observed in the plasma. This new platelet property may lead to the development of a biomarker for very early detection of tumor recurrence. Whereas an association between new blood vessel growth and platelets has long been recognized, the cause and effect relationship linking the two has been unclear. Given that platelets contain both stimulators and inhibitors of angiogenesis, packaged into a homogeneous population of α-granules, the question becomes how can platelets have either a proangiogenic or antiangiogenic effect? The release of a mixture of both pro- and antiangiogenic regulatory proteins from platelets should cancel the effect of each other. Several groups have demonstrated that platelets can preferentially secrete a platelet releasate that has either a pro- or antiangiogenic effect. The treatment of human platelets with the selective protease activated receptor (PAR)-4 agonist resulted in release of endostatin-containing granules but not vascular endothelial growth factor–containing granules, whereas the selective PAR-1 agonist liberated vascular endothelial growth factor but not endostatin, containing granules. This differential release is also observed with physiologic agonists. Activation of human platelets with adenosine diphosphate stimulates the release of vascular endothelial growth factor but not endostatin, whereas thromboxane A2 releases endostatin but not vascular endothelial growth factor. Activation with adenosine diphosphate also promotes the formation of capillary structures by human umbilical vein endothelial cells in vitro. Conversely, thromboxane A2–activated releasate inhibits formation of capillary structures. We have also tested the hypothesis that cancer cells preferentially stimulate platelets to secrete their proangiogenic payload, providing a mechanism for how tumors may hijack platelets to promote new blood vessel growth. In support of this idea, the MCF-7 breast cancer cell line stimulates secretion of vascular endothelial growth factor and a proangiogenic releasate from platelets. Interestingly, the antiplatelet agent aspirin blocked platelet-mediated angiogenesis after introduction to the MCF-7 cells, pointing to a potential mechanism for how aspirin may influence malignancy. Taken together, these data suggest that manipulation of differentially mediated release of angiogenesis regulatory proteins from platelets may provide a new modality for treatment of cancer. A better understanding of the mechanisms by which platelets release angiogenic regulatory proteins should yield strategies for therapeutic benefit.

Platelets and Immunity
Platelets play a role in immunity by expressing members of the toll-like receptor (TLR) family. TLRs are a class of proteins that play an essential role in the innate immune system by recognizing molecules that are broadly shared by pathogens. TLRs have been extensively characterized in macrophages, dendritic cells, and neutrophils and support immune activation in response to conserved molecular motifs on pathogens. Although platelets express TLRs 1 through 9, most work has focused on TLRs 1 to 6, which are expressed on the surface of the platelet and believed to trap bacteria for elimination by phagocytes. We recently demonstrated that the TLR9 transcript is specifically up-regulated during platelet production and is localized to a novel electron-dense tubular system named the T-granule. TLR9 colocalizes with protein disulfide isomerase and is associated with either vesicle–associated membrane protein 8 or vesicle–associated membrane protein 7, which are molecules involved in vesicle fusion that regulate TLR9 distribution in platelets during activation. Type IV collagen specifically increases P-selectin, a cell adhesion molecule, and TLR9 surface expression and augments oligodeoxynucleotide sequestration and platelet aggregation upon the addition of viral and bacterial oligodeoxynucleotides. Increased surface expression of TLR9 in platelets and type C CpG sequestration may aid in the regulation and sequestration of circulating levels of bacterial DNA in the blood and consequently help manage the inflammatory response after lysis of bacterial cells. A more thorough understanding of the function that TLRs play in regulating the activation of platelets will likely yield new therapies for the treatment of cardiovascular infections.

Conclusions
The transition from megakaryocyte to released platelets is an elaborate and complex process. Although the basic
mechanisms of platelet production have been investigated, elucidating the specific molecular controls and cellular events involved in platelet formation and release is an important goal. Among the major questions regarding platelet biogenesis that have yet to be addressed include the following: (1) What factors induce proplatelet formation in mature megakaryocytes? (2) How can we mimic human physiology to generate a bioreactor that produces in vitro platelets? (3) What are the regulatory signals that direct the sequence of developmental events that drives platelet production? (4) How can we engineer designer platelets that will deliver biologically active molecules? (5) What mechanisms contribute to the giant platelets observed in macrothrombocytopenias? Further examination of the molecular, cellular, and biochemical studies of megakaryocytes as they transition into platelets will provide a clearer understanding of these processes. This knowledge may lead to the ex vivo generation of platelets or in vivo therapies aimed at enhancing platelet production in patients with thrombocytopenia.

References


